ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products is medical classification list by Centers for Medicare and Medicaid Services (CMS).
ICD-10-PCS code range (XW0), contains ICD-10-PCS codes for Nervous System, New Technology, Anatomical Regions, Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
PCS Tables
| X New Technology |
| W Anatomical Regions |
| 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|---|---|---|---|
| Character 4 | Character 5 | Character 6 | Character 7 |
Body System (Character 4)
0 Skin | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Daratumumab and Hyaluronidase-fihj | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Talquetamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 4 Teclistamab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Satralizumab-mwge | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal AntibodyH Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Elranatamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1 | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Epcoritamab Monoclonal Antibody | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T COVID-19 Vaccine Dose 2U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3 | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W COVID-19 Vaccine Booster | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
2 Muscle | Approach (Character 5) 0 Open | Substance (Character 6) D Engineered Allogeneic Thymus Tissue | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
5 Peripheral Artery | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T Melphalan Hydrochloride Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
9 Nose | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Esketamine Hydrochloride | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 3 Maribavir Anti-infective | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 8 Uridine Triacetate | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) F Other New Technology Therapeutic SubstanceJ Apalutamide Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) J Quizartinib Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) K Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) L Erdafitinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) N SER-109 | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Venetoclax Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) T RuxolitinibV Gilteritinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
G Upper GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) X Broad Consortium Microbiota-based Live Biotherapeutic Suspension | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
Q Cranial Cavity and Brain | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Eladocagene exuparvovec | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
V Bones | Approach (Character 5) 0 Open | Substance (Character 6) P Antibiotic-eluting Bone Void Filler | Qualifier (Character 7) 7 New Technology Group 7 |
December 31, 1969
The Medicare Advantage organization says they are being held to unreasonable standards. Health Net of California Inc. was recently called out by the Office of Inspector General OIG for failing to subm... [ Read More ]
December 31, 1969
Reduce the clutter on your home page with one click. Codify offers a lot of tools on its home page but you dont always want all of them expanded at once. There is a simple way to maximize the tools yo... [ Read More ]
December 31, 1969
Strategies for unlocking a dialogue with physicians. As auditors we bridge the gap between medical coding accuracy and financial stability in healthcare organizations. Its our role to knock on the doo... [ Read More ]
December 31, 1969
Encourage patients to take stock of their relationship with alcohol. From Dry January and Dry July to Sober September and Sober October the monthlong abstinence trend of shunning alcohol has gained gr... [ Read More ]
December 31, 1969
Meet a member who never stops learning and growing. Each month AAPC selects a member who demonstrates exemplary leadership qualities. This month weve chosen Jennifer Lavoie RN CPC. Lavoie has enjoyed ... [ Read More ]
... [ Read More ]